Vanguard Group Inc. Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Vanguard Group Inc. decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,530,017 shares of the medical device company’s stock after selling 904,784 shares during the period. Vanguard Group Inc. owned 0.12% of DexCom worth $3,618,639,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of DXCM. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA increased its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares in the last quarter. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter valued at $38,000. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $75.32 on Tuesday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $29.43 billion, a P/E ratio of 52.67, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $83.24 and a two-hundred day simple moving average of $77.07.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DXCM shares. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.